Now, Honigberg and colleagues describe an orally available, potent and selective inhibitor of the B-cell receptor (BCR) signalling molecule Bruton's tyrosine kinase (BTK), which shows promising ...

Opens in a new tab or window SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet counts in heavily pretreated patients ...

ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITPPivotal phase 3 data ...